Precise treatment of Crohn's disease with biological agents based on genetics and intestinal microbiota study

Precise treatment of Crohn's disease with biological agents

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-RPC-16009388

Enrollment

Unknown

Registered

2016-10-13

Start date

2016-11-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn's disease

Interventions

treatment group:iv injection of IFX

healthy control grooup:regular diet

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Active CD patients are recruited in this study (aged 18-60 yrs). IFX (5 mg/kg) is injected iv at weeks 0, 2 and 6. The side-effects are observed including fevel, respiratory difficulties, itching, urticaria and other allergic reactions. The CDAI is less than 150 or decreases more than 70, the response to IFX is marked. Otherwise, the CDAI is increased or not changed, the failure is considered.

Exclusion criteria

Exclusion criteria: Infectious diseases, Children, Old people, Pregnancy, Presence of Abdominal abscess, perforation, intestinal obstruction.

Design outcomes

Primary

Measure	Time frame
efficacy, change of gene expression, change of intestinal microbiota;	—

Countries

China

Contacts

Public ContactLiu Zhanju

The Shanghai Tenth People'e Hospital

liuzhanju88@126.com+86 18917683431

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026